To understand the role of SHP2 pY62 in patients, we determined its abundance and enrichment across genomically defined human tumor types based on publicly available data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC)37. This evidence concerns the gene PTPN11 and neoplasm.